|
Indication(s)a
|
Aged 41–50 years
|
Aged > 50 years
|
|---|
|
n (%) safety population (n = 334)
|
n (%) comorbid population(n = 161)
|
n (%) safety population(n = 158)
|
n (%) comorbid population(n = 85)
|
|---|
|
Arterial hypertension
|
23 (6.9 %)
|
23 (14.3 %)
|
19 (12.0 %)
|
19 (22.4 %)
|
|
Diabetes mellitus
|
5 (1.5 %)
|
5 (3.1 %)
|
3 (1.9 %)
|
3 (3.5 %)
|
|
Dyslipidaemia
|
7 (2.1 %)
|
7 (4.3 %)
|
12 (7.6 %)
|
12 (14.1 %)
|
|
Cardiovascular disorders, otherb
|
10 (3.0 %)
|
10 (6.2 %)
|
8 (5.1 %)
|
8 (9.4 %)
|
|
Infectionc
|
6 (1.8 %)
|
6 (3.7 %)
|
2 (1.3 %)
|
2 (2.4 %)
|
|
Malignancies
|
0 (0.0 %)
|
0 (0.0 %)
|
2 (1.3 %)
|
2 (2.4 %)
|
|
Autoimmune disease
|
13 (3.9 %)
|
13 (8.1 %)
|
5 (3.2 %)
|
5 (5.9 %)
|
- aAdditional medications taken by patients were recorded, and the comorbidity data presented here is derived from the indications for these co-medications.
- bThe category of ‘other cardiovascular disorders’ is derived from additional medications with the following indications: anti-aggregation, stroke prevention, thromboembolism, arrhythmia and vascular disease.
- cInfection for which patients received antibiotics excluding sexual transmitted disease.
